All articles tagged with #weightloss
A review of research indicates that individuals who stop using GLP-1 drugs like Ozempic and Wegovy for weight loss tend to regain their lost weight within approximately 18 months, and this regain occurs faster than with behavioral methods like dieting or exercise. To maintain health benefits after discontinuing these medications, lasting lifestyle changes are essential.
Doctors warn that weight-loss drugs like Ozempic and Wegovy, originally for diabetes, carry risks such as side effects and potential weight regain after stopping, emphasizing the importance of lifestyle changes and caution against viewing these medications as quick fixes.
Strategic fasting, a mindful and structured eating pattern, may be an effective way to lose belly fat by improving how the body stores and uses energy, offering an alternative to simply exercising more or reducing calories.
Many users of GLP-1 drugs like Ozempic struggle to stop using them due to intense hunger and weight regain, suggesting a potential lifelong dependency. While some, like Ellen Ogley, maintain weight loss through lifestyle changes, others experience significant weight regain, highlighting the importance of healthy habits during treatment. Experts recommend developing an exit strategy that includes lifestyle modifications to sustain weight loss after discontinuing the medication.
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.
Eli Lilly's new obesity pill helps patients maintain weight loss after switching from injections like Wegovy and Zepbound, with promising trial results suggesting it could serve as a needle-free long-term treatment option, potentially capturing significant market share in the growing weight loss drug industry.
The WHO highlights the potential of weight loss drugs like Mounjaro as a significant breakthrough in treating obesity, emphasizing the need for increased access, affordability, and comprehensive support, while noting these medications are not a standalone solution and should be part of broader lifestyle changes.
Researchers in China have developed fat-blocking microbeads made from green tea, vitamin E, and seaweed that showed promising results in rats fed a high-fat diet, suggesting a potential noninvasive dietary strategy for weight loss. Human trials are underway to confirm safety and effectiveness, and the microbeads could serve as an alternative to drugs and surgery for obesity management.
The article discusses the issue of loose, sagging skin that often results from rapid weight loss due to obesity drugs like tirzepatide and others, highlighting that while these medications improve health, they can leave individuals self-conscious about excess skin, which is difficult to address with creams or treatments.
A new drug called ecnoglutide shows promise as a treatment for type 2 diabetes and weight loss, potentially rivaling Ozempic, with clinical trials indicating it may be more effective in lowering blood sugar and promoting weight loss than dulaglutide, and similar or better than semaglutide, though it is not yet approved for market.
Eli Lilly's obesity pill, orforglipron, despite underwhelming trial data compared to Novo Nordisk's oral semaglutide, remains a competitive option due to its potential advantages in manufacturing, cost, and ease of use, with market predictions favoring Lilly's larger global rollout and market share in the future.
The article discusses how the mainstream adoption of GLP-1 drugs for weight loss has led to social tensions, exemplified by Marcia Berry's experience of being ghosted by her hairstylist after using a non-branded GLP-1 drug to lose weight, highlighting issues of jealousy and judgment surrounding these medications.
A study on mice suggests that weight loss drugs like Ozempic and Wegovy may cause loss of lean mass, including organs like the liver and some muscles, raising concerns about potential impacts on muscle strength and organ health in humans, especially older adults. Further research is needed to confirm these effects in humans and assess health risks.
Twin sisters Tonia Brown and Tonie Ervin, weighing around 380-400 pounds, successfully lost nearly 400 pounds through a combination of ketogenic diet, walking, and bariatric surgery, with their journey highlighting the importance of support, lifestyle changes, and perseverance.
The article discusses the psychological and physical impacts of Ozempic, highlighting its role in transforming attitudes towards food and weight, the risks of rebound weight gain after stopping the drug, and concerns about long-term safety and regulation, emphasizing the need for careful management and support for users.